GWM
PLX icon

Geneos Wealth Management’s Protalix BioTherapeutics PLX Stock Holding History

Geneos Wealth Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86K Buy
+800
New +$1.69K ﹤0.01% 2337
2023
Q4 		– Sell
-2,000
Closed -$3.32K – 2156
2023
Q3 		$3.32K Buy
+2,000
New +$3.59K ﹤0.01% 1843

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geneos Wealth Management's PLX Position: Q2 2026 in Review

Geneos Wealth Management opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 800 shares worth $1.86K. The stake represents ﹤0.01% of the portfolio and ranks #2337 among its holdings. This is a return to the name: Geneos Wealth Management previously reported a position in PLX as recently as Q3 2023.

Geneos Wealth Management first reported a position in PLX in Q3 2023 and has held it in 2 quarters since. The position peaked at $3.32K in Q3 2023. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Geneos Wealth Management held 800 shares of Protalix BioTherapeutics worth $1.86K as of Q2 2026.
  • Protalix BioTherapeutics was a new Geneos Wealth Management position in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #2337 holding.
  • Geneos Wealth Management first reported a position in Protalix BioTherapeutics in Q3 2023 and has held it in 2 quarters since.
  • Geneos Wealth Management's Protalix BioTherapeutics position peaked at $3.32K in Q3 2023.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.